OP002

OP002 is an investigational small molecule drug candidate being developed by Opimend, a portfolio company of the Drug Rediscovery Group. It is specifically designed as a pain reduction alternative for individuals who use opioids, aiming to provide effective analgesia through non-traditional pathways or by modulating the neurobiological responses associated with opioid use. As a product of the Drug Rediscovery Group's repurposing platform, OP002 represents a new therapeutic application for a previously approved pharmaceutical agent. The development of OP002 addresses the critical clinical need for pain management strategies that can reduce the reliance on traditional opioids or mitigate the development of opioid tolerance and related side effects.

Other names

Opimend-Pain Reduction Alternative in Opioid Users